Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Current Developments and Recent Advances in Musculoskeletal Tumor Imaging
Peterson, Jeffrey J.

Seminars in Musculoskeletal Radiology | May 14, 2013 | Volume: 17 | Issue: 02 | Pages: 099-100

10.1055/s-0033-1343093 | PMID 23673541 Get It

Current Developments and Recent Advances in Musculoskeletal Tumor Imaging
Bridges, Mellena D., Kransdorf, Mark J.

Seminars in Musculoskeletal Radiology | May 14, 2013 | Volume: 17 | Issue: 02 | Pages: 145-155

10.1055/s-0033-1343070 | PMID 23673546 Get It

Current Concepts in MRI of Focal and Diffuse Malignancy of Bone Marrow
Johnson, Geoffrey B. , Wenger, Doris E. , Howe, Benjamin M. , Johnson, Geoffrey B. , Johnson, Geoffrey B , Johnson, Geoffrey B

Seminars in Musculoskeletal Radiology | May 14, 2013 | Volume: 17 | Issue: 02 | Pages: 137-144

10.1055/s-0033-1343069 | PMID 23673545 Get It

Assessing Competence for Reentry
Steadman, Randolph H., Cole, Daniel J.

Anesthesiology | May 14, 2013 | Volume: 119 | Issue: 1 | Pages: 16-18

10.1097/aln.0b013e3182976334 | PMID 23673523 Get It

Matrix metalloproteinase‐9 as a therapeutic target for the progression of fulminant liver failure with hepatic encephalopathy: A pilot study in mice
Hori, Tomohide , Üemoto, Shinji , Walden, Lindsay B., Baine, Ann‐Marie T., Kogure, Takayuki , Nguyen, Justin H. , Chen, Feng , Hata, Toshiyuki

Hepatology Research | May 14, 2013 | Volume: 44 | Issue: 6 | Pages: 651-662

10.1111/hepr.12161 | PMID 23672352 Get It

AimIf progressive liver injury and subsequent hepatic encephalopathy can be prohibited in fulminant liver failure (FLF), it would be ideal for intensive care of FLF and provide an expanded opportunity for liver transplantation (LT). We hypothesized that matrix metalloproteinase (MMP)‐9 plays an important role in FLF progression, and investigated MMP‐9 behaviors in a murine FLF model, especially at the coma stage.MethodsThe murine FLF model with azoxymethane recapitulates FLF in humans. The detailed coma status was evaluated, on the assumption that LT is indicated at early, but not late, stage 3. To investigate whether MMP‐9 deletion or reduction has beneficial effects, an MMP‐9 inhibitor (GM6001) and transfection of tissue inhibitor of metalloproteinases (TIMP)‐1 cDNA were used. Mice were divided into five groups: control; FLF; FLF with GM6001 pretreatment; FLF with TIMP‐1 plasmid transfection 24 h before disease onset; and FLF with TIMP‐1 plasmid transfection 48 h before disease onset. Neurological findings, including survival, were followed. Samples were obtained at early and late stage 3. Biochemical examinations and histopathological assessments were performed. The expression and function of MMP‐9 and TIMP‐1 were evaluated by western blotting and zymography. A brain permeability study was also performed.ResultsMMP‐9 was strongly increased in FLF. The MMP‐9 inhibitions worked well, and prolonged the survival, interval to stage 3 and duration of early stage 3. MMP‐9 inhibition improved the liver and subsequent brain injuries at early stage 3, with no remarkable improvements at late stage 3.ConclusionMMP‐9 has therapeutic potential for FLF progression.
Health‐related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
Harrison, Claire , Kiladjian, Jean‐Jacques , Al‐Ali, Haifa Kathrin , Gisslinger, Heinz , Knoops, Laurent, Squier, Margaret, Sirulnik, Andres, Mendelson, Estella, Zhou, Xiaolei , Copley‐Merriman, Catherine , Hunter, Deborah, Levy, Richard S., Cervantes, Francisco , Passamonti, Francesco , Barbui, Tiziano , Mesa, Ruben A. , Barosi, Giovanni , Vannucchi, Alessandro M. , Kiladjian, Jean-Jacques , Passamonti, Francesco

British Journal of Haematology | May 14, 2013 | Volume: 162 | Issue: 2 | Pages: 229-239

10.1111/bjh.12375 | PMID 23672349 Get It

SummaryPatients with myelofibrosis (MF) have significant debilitating symptoms, physical disabilities, and poor health‐related quality of life (HRQoL). Here, we report post‐hoc analyses of the impact of ruxolitinib, a potent and selective JAK1 and JAK2 inhibitor, on disease‐related symptoms and HRQoL in MF patients from the large phase 3 COMFORT‐II study (N = 219). During the follow‐up period of 48 weeks, HRQoL and MF‐associated symptoms improved from baseline for ruxolitinib‐treated patients but remained the same or worsened for best available therapy (BAT)‐treated patients. Based on the European Organization for Research and Treatment of Cancer QoL Questionnaire core 30 items (EORTC QLQ‐C30), treatment‐induced differences in physical and role functioning, fatigue, and appetite loss significantly favoured ruxolitinib versus BAT from week 8 (P < 0·05) up to week 48 (P < 0·05). Ruxolitinib resulted in significantly higher response rates in global health status/QoL and Functional Assessment of Cancer Therapy‐Lymphoma (FACT‐Lym) summary scores versus BAT at most time points (P < 0·05). Significant improvements in the Lymphoma subscale (including symptoms of pain, fever, itching, fatigue, weight loss, loss of appetite, and other patient concerns), FACT‐General, FACT‐Lym trial outcome index, and FACT‐Lym total were also observed with ruxolitinib versus BAT starting at week 8 and continuing thereafter. Overall, these data demonstrated that ruxolitinib improved HRQoL in MF patients and further support the use of ruxolitinib for the treatment of symptomatic MF.
Overall survival advantage with partial nephrectomy: A bias of observational data?
Shuch, Brian , Lai, Julie , Vourganti, Srinivas , Kim, Simon P. , Dick, Andrew W., Chow, Wong‐Ho , Saigal, Chris, Project, the Urologic Diseases in America, Hanley, Janet M. , Setodji, Claude Messan , Project, the Urologic Diseases in America

Cancer | May 14, 2013 | Volume: 119 | Issue: 16 | Pages: 2981-2989

10.1002/cncr.28141 | PMID 23674264 Get It

BACKGROUNDPartial nephrectomy (PN) and radical nephrectomy (RN) are standard treatments for a small renal mass. Retrospective studies suggest an overall survival (OS) advantage, however a randomized phase 3 trial suggests otherwise. The effects of both surgical modalities on OS were evaluated compared with controls.METHODSA matched cohort study was performed using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare dataset. Individuals treated with PN or RN for localized renal cell carcinoma (RCC) measuring ≤4 cm were compared with 2 control groups (non–muscle‐invasive bladder cancer (BCC) and noncancer controls (NCC). Using a greedy algorithm, RCC groups were matched with controls by demographics and comorbidities. OS for surgical groups and controls were compared. The cause of death was evaluated for cancer groups when differences in OS were noted.RESULTSPatients undergoing PN and RN were matched with controls. All cancer groups had >95% 10‐year cancer‐specific survival (CSS). Median OS was similar between RN (9.05 years) and BCC (8.67 years; P = .067) and NCC (8.77 years; P = .49). Median OS was improved for PN (10.45 years) compared with BCC (8.75 years; P<.001) and NCC controls (8.76 years; P<.001). A multivariate Cox hazards model demonstrated that PN improved OS compared with NCC (hazard ratio, 1.257; P<.001) and BCC (hazard ratio, 1.364; P<.001).CONCLUSIONSRN patients had similar OS compared with controls, suggesting that this treatment modality does not compromise survival. Patients undergoing PN had improved OS compared with controls, suggesting possible selection bias. The apparent survival advantage conferred by PN in SEER‐Medicare case series is likely the result of selection bias involving unmeasured confounders. Cancer 2013;119:2981—2989. © 2013 American Cancer Society.
Cardiac Mri of Acute Coronary Syndrome
Khan, Shamruz Akerem, Williamson, Eric E. , Foley, Thomas A. , Cullen, Ethany L., Young, Phillip M. , Araoz, Philip A.

Future Cardiology | May 14, 2013 | Volume: 9 | Issue: 3 | Pages: 351-370

10.2217/fca.13.23 | PMID 23668741 Get It

Multiple Myeloma Mimicking Metastatic Pancreas Cancer
Sher, Taimur , Bhat, Seema A. , Jitawatanarat, Potjana, Desai, Nisarg , Qiu, Jingxin , Ma, Wen W., Ma, Wen W.

Journal of Clinical Oncology | May 14, 2013 | Volume: 31 | Issue: 18 | Pages: e297-e299

10.1200/jco.2012.44.8845 | PMID 23669220 Get It

Patient‐controlled analgesia‐based pain control strategy for minimally‐invasive pectus excavatum repair
Bogert, James N. , Potter, D. Dean , Moir, Christopher R. , Haile, Dawit T. , Wilder, Robert T.

Surgical Practice | May 14, 2013 | Volume: 17 | Issue: 3 | Pages: 101-104

10.1111/1744-1633.12017 Get It

AimThe minimally‐invasive Nuss procedure has become the preferred technique for pectus excavatum repair. This procedure is still associated with significant postoperative pain, and an optimal pain‐management strategy is yet to be determined. The purpose of this study was to compare the efficacy of patient‐controlled analgesia (PCA) to thoracic epidural analgesia (TEA).Patients and MethodsWe retrospectively reviewed 112 charts from a single paediatric centre. Patients were grouped according to pain‐management strategy: 90 patients received a PCA, and 22 patients received TEA. Outcomes included length of hospitalization and daily pain scores, operating room time and duration of Foley catheterization.ResultsDemographic data were similar between the two groups. The daily pain scores were not statistically different between the groups. Length of hospitalization was similar (PCA: 4.6 days, epidural: 4.3 days, P = 0.33). The PCA group required less operating room time (2:44 vs 2:58, P = 0.04) and shorter Foley catheter duration (2.1 days vs 2.5 days, P = 0.04).ConclusionIn our patient population, TEA for the Nuss procedure does not offer an advantage over PCA‐centred analgesia in terms of subjective daily pain scores or length of hospital stay. The potential risks of TEA need to be carefully considered in this patient population.